What is Seres Therapeutics, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Seres Therapeutics, Inc.'s reported free cash flow gives $2.75 per share. The share price was $3.52 on September 25, 2026, 28% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -10.0% | 10.0% | $2.39 | -32% |
| Base | -5.0% | 9.0% | $2.75 | -22% |
| Bull | 0.0% | 8.0% | $3.43 | -3% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $2.99 | $3.06 | $3.15 | $3.26 | $3.40 |
| 8.0% | $2.81 | $2.86 | $2.91 | $2.98 | $3.06 |
| 9.0% | $2.68 | $2.71 | $2.75 | $2.79 | $2.84 |
| 10.0% | $2.58 | $2.60 | $2.63 | $2.66 | $2.69 |
| 11.0% | $2.50 | $2.52 | $2.54 | $2.56 | $2.58 |
Where the presets come from
Base: years 1 to 5 grow at Seres Therapeutics, Inc.'s revenue growth rate over the last 7 fiscal years (-40.0% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions